ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

Background: Macrophage activation-like syndrome (MALS) and complex immune dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We aimed to investigate the effect of personalized immunotherapy on clinical improvement of critical COVID-19. Methods: In this open-label prosp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Eleni Karakike, George N. Dalekos, Ioannis Koutsodimitropoulos, Maria Saridaki, Chryssa Pourzitaki, Georgios Papathanakos, Antigone Kotsaki, Stamatios Chalvatzis, Vasiliki Dimakopoulou, Nikolaos Vechlidis, Elisabeth Paramythiotou, Christina Avgoustou, Aikaterini Ioakeimidou, Elli Kouriannidi, Apostolos Komnos, Evangelia Neou, Nikoletta Rovina, Eleni Stefanatou, Haralampos Milionis, George Nikolaidis, Antonia Koutsoukou, Georgia Damoraki, George Dimopoulos, Vassileios Zoumpos, Jesper Eugen-Olsen, Karolina Akinosoglou, Nikolaos K. Gatselis, Vasilios Koulouras, Eleni Gkeka, Nikolaos Markou, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis
Formato: article
Lenguaje:EN
Publicado: Karger Publishers 2021
Materias:
interleukin 1 receptor antagonist protein
tocilizumab
respiratory distress syndrome
covid-19
macrophage activation
monocytes
Medicine
R
Internal medicine
RC31-1245
Acceso en línea:https://doaj.org/article/1a1b1ce9f0cc42099e276c4bad6ad8ae
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares